Morbidity and Mortality Follow Up for the Scleroderma Lung Study

Overview

The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.

Full Title of Study: “Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1”

Study Type

  • Study Type: Observational
  • Study Design
  • Study Primary Completion Date: June 2013

Detailed Description

Retrospective and prospective data will be collected about patients who participated in the Scleroderma Lung Study (SLS). An attempt will be made to include all of the participants of the Scleroderma Lung Study, who were reported as alive at the end of that study. A total of 158 subjects (79 per treatment arm) were randomized on the original Scleroderma Lung Study. Of those, 109 subjects completed the study. A single telephone interview with the participants to assess the occurrence of severe events and a review of the participant's medical records may be conducted. The outcome information will be combined with information collected about all participants in the SLS study. The data being collected includes information on mortality, development of cancers, development of organ failure, and performance status.

Interventions

  • Other: Followup survey

Arms, Groups and Cohorts

  • Patients who received cyclophosphamide
    • Patients who received cyclophosphamide on the Scleroderma Lung Study
  • Patients who received placebo
    • Patients who received placebo on the Scleroderma Lung Study

Clinical Trial Outcome Measures

Primary Measures

  • Time to death or first organ failure
    • Time Frame: 9-12 years

Participating in This Clinical Trial

Inclusion Criteria

  • Participation in the Scleroderma Lung Study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Duke University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Keith Sullivan, MD, Study Chair, Duke University
    • Daniel Furst, MD, Study Chair, University of California, Los Angeles
    • Donald Tashkin, MD, Principal Investigator, University of California, Los Angeles

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.